IP Library Granted Patent US 9,528,088
Granted Patent B2
US 9,528,088 · App. 14/086,841 · Granted Dec 27, 2016

Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,528,088
App. No.
14/086,841
Granted
Dec 27, 2016
Kind
B2
Abstract

The present invention relates generally to methods for stimulating T cells, and more particularly, to methods to eliminate undesired (e.g., autoreactive, alloreactive, pathogenic) subpopulations of T cells from a mixed population of T cells, thereby restoring the normal immune repertoire of said T cells. The present invention also relates to compositions of cells, including stimulated T cells having restored immune repertoire and uses thereof.

Claims (10)

1. A method for activating and expanding naïve T cells present in a mixed population of T cells comprising naïve T cells and antigen-specific memory T cells, the method comprising:

contacting the mixed population of T cells with a surface having attached thereto agents with binding activity to cell surface moieties on the surfaces of T cells in the mixed population,

thereby (a) expanding naïve T cells, and (b) deleting antigen-specific memory T cells present in the mixed population of T cells,

wherein the agents having binding affinity for CD3 protein complexes and CD28 proteins, and

wherein the ratio of surface to cells is at least 5:1.

2. The method of claim 1 , wherein one or both of the agents are antibodies or an antibody fragments.

3. The method of claim 1 , wherein one of the agents is an anti-CD3 antibody or an anti-CD3 antibody fragment.

4. The method of claim 1 , wherein one of the agents is an anti-CD28 antibody or an anti-CD28 antibody fragment.

5. The method of claim 1 , wherein an anti-CD3 antibody or an anti-CD3 antibody fragment and an anti-CD28 antibody or an anti-CD28 antibody fragment are co-localized on the same surface.

6. The method of claim 1 , wherein the ratio of surface to cells is between 5:1 and 10:1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2016
From: BERENSON, RONALD J.; BONYHADI, MARK; KALAMASZ, DALE
To: XCYTE THERAPIES, INC.
Reel/Frame 040068/0286 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2016
From: XCYTE THERAPIES, INC.
To: INVITROGEN CORPORATION
Reel/Frame 040068/0323 →
MERGER AND CHANGE OF NAME Recorded Oct 19, 2016
From: INVITROGEN CORPORATION; LIFE TECHNOLOGIES CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 040068/0410 →